Gapping up
Briefing note: With S&P futures up over 1% this morning, many stocks may be gapping higher that are not idicated below.
In reaction to strong earnings/guidance: ZAGG +20.1%, BIOD +12.8%, RAD +9.9%, AKS +8.3%, JBL +6.1%, ORCL +4.7%, LUB +4.1%, A.CN +2%, APOG +0.9%, STLD +0.9%
M&A news: APP +8.7% (LATimes discusses M&A rumors in APP following news that Charney was suspended as president and CEO), ALU +5.7% (may be in merger talks with Nokia (NOK), according to reports), PTRY +2.2% (to be acquired by Couche-Tard for $36.75/share in cash), MRK +1.7% (announced that it has acquired, through a subsidiary, OncoEthix for upfront payment of $110 mln), NOK +1.1% (may be in merger talks with ALU)
Select metals/mining stocks trading higher: AU +4.8%, CDE +4.6%, IAG +3.3%, ABX +3.2%, KGC +3%, HL +2.4%
Select oil/gas related names showing strength: KEG +18.6%, EXXI +12.7%, MPO +9.4%, PBR +7.8%, PWE +7.8%, PVA +7.3%, LINE +7%, SSL +6.5%, OAS +6.1%, WLL +5.6%, SDRL +4.9%, CHK +3.6%, STO +3.2%, HAL +3%
Other news: MBT +23.6% (Russian related name rebounding), VIP +20.2% (Russian related name rebounding), TTPH +16.3% (announced positive top-line results from Phase 3 IGNITE 1 clinical trial of Eravacycline in complicated intra-abdominal infections), AGEN +9% (announced that its partner GlaxoSmithKline (GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint), CRK +8% (still checking), MPEL +5.8% (disclosed Macau framework agreement), YNDX +4.7% (Russian related name rebounding), HTZ +4.2% (still checking), AGIO +3.4% (favorable commentary on Wednesday's Mad Money), SNE +2.9% (cancels December 25 release of 'The Interview,' according to reports), NAV +2.8% (Carl Icahn disclosed 19.99% active stake in 13D filing), RRD +2.8% (favorable commentary on Wednesday's Mad Money), ONNN +2.5% (announced CMOS operational amplifiers that deliver zero drift operation and quiescent current for front-end amplifier circuits and power mgmt designs), ORAN +2.5% (Funds advised by Apax Partners agree to sell Orange Switzerland to NJJ Capital), WYNN +2.2% (rebounding after recent slide),EXAM +2.1% (to replace OPLK in the S&P SmallCap 600), AMGN +1.5% (increased quarterly dividend 30% to $0.79 from $0.61 per share), CGEN +1.1% (enters Immuno-Oncology research collaboration with Johns Hopkins University), HPQ +1% (favorable commentary on Wednesday's Mad Money), AZN +0.9% (announced that the EC has granted Marketing Authorization for Lynparza as a first-in-class treatment for advanced BRCA-mutated ovarian cancer)
Analyst comments: OVAS +14.2% (released data yday morning; upgraded to Outperform from Neutral at Wedbush), GOL +5.6% (upgraded to Buy from Neutral at BofA/Merrill), BLOX +4.4% (upgraded to Outperform from Sector Perform at Pacific Crest), BHI +2.9% (upgraded to Outperform at RBC Capital Mkts), FDX +1.9% (upgraded to Buy from Neutral at Goldman; tgt $211 -- Added to Conviction Buy List), GLW +1.9% (upgraded to Buy from Neutral at Citigroup), JOY +1.8% (upgraded to Neutral from Underperform at Longbow), LNKD +1.8% (initiated with a Outperform at Wells Fargo), THC +1.7% (initiated with a Buy at Sterne Agee
)
Briefing note: With S&P futures up over 1% this morning, many stocks may be gapping higher that are not idicated below.
In reaction to strong earnings/guidance: ZAGG +20.1%, BIOD +12.8%, RAD +9.9%, AKS +8.3%, JBL +6.1%, ORCL +4.7%, LUB +4.1%, A.CN +2%, APOG +0.9%, STLD +0.9%
M&A news: APP +8.7% (LATimes discusses M&A rumors in APP following news that Charney was suspended as president and CEO), ALU +5.7% (may be in merger talks with Nokia (NOK), according to reports), PTRY +2.2% (to be acquired by Couche-Tard for $36.75/share in cash), MRK +1.7% (announced that it has acquired, through a subsidiary, OncoEthix for upfront payment of $110 mln), NOK +1.1% (may be in merger talks with ALU)
Select metals/mining stocks trading higher: AU +4.8%, CDE +4.6%, IAG +3.3%, ABX +3.2%, KGC +3%, HL +2.4%
Select oil/gas related names showing strength: KEG +18.6%, EXXI +12.7%, MPO +9.4%, PBR +7.8%, PWE +7.8%, PVA +7.3%, LINE +7%, SSL +6.5%, OAS +6.1%, WLL +5.6%, SDRL +4.9%, CHK +3.6%, STO +3.2%, HAL +3%
Other news: MBT +23.6% (Russian related name rebounding), VIP +20.2% (Russian related name rebounding), TTPH +16.3% (announced positive top-line results from Phase 3 IGNITE 1 clinical trial of Eravacycline in complicated intra-abdominal infections), AGEN +9% (announced that its partner GlaxoSmithKline (GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint), CRK +8% (still checking), MPEL +5.8% (disclosed Macau framework agreement), YNDX +4.7% (Russian related name rebounding), HTZ +4.2% (still checking), AGIO +3.4% (favorable commentary on Wednesday's Mad Money), SNE +2.9% (cancels December 25 release of 'The Interview,' according to reports), NAV +2.8% (Carl Icahn disclosed 19.99% active stake in 13D filing), RRD +2.8% (favorable commentary on Wednesday's Mad Money), ONNN +2.5% (announced CMOS operational amplifiers that deliver zero drift operation and quiescent current for front-end amplifier circuits and power mgmt designs), ORAN +2.5% (Funds advised by Apax Partners agree to sell Orange Switzerland to NJJ Capital), WYNN +2.2% (rebounding after recent slide),EXAM +2.1% (to replace OPLK in the S&P SmallCap 600), AMGN +1.5% (increased quarterly dividend 30% to $0.79 from $0.61 per share), CGEN +1.1% (enters Immuno-Oncology research collaboration with Johns Hopkins University), HPQ +1% (favorable commentary on Wednesday's Mad Money), AZN +0.9% (announced that the EC has granted Marketing Authorization for Lynparza as a first-in-class treatment for advanced BRCA-mutated ovarian cancer)
Analyst comments: OVAS +14.2% (released data yday morning; upgraded to Outperform from Neutral at Wedbush), GOL +5.6% (upgraded to Buy from Neutral at BofA/Merrill), BLOX +4.4% (upgraded to Outperform from Sector Perform at Pacific Crest), BHI +2.9% (upgraded to Outperform at RBC Capital Mkts), FDX +1.9% (upgraded to Buy from Neutral at Goldman; tgt $211 -- Added to Conviction Buy List), GLW +1.9% (upgraded to Buy from Neutral at Citigroup), JOY +1.8% (upgraded to Neutral from Underperform at Longbow), LNKD +1.8% (initiated with a Outperform at Wells Fargo), THC +1.7% (initiated with a Buy at Sterne Agee
)